What Is Microdose Tirzepatide? Understanding Ultra-Low-Dose GLP-1 Therapy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdose tirzepatide refers to weekly doses below the FDA-approved 2.5 mg starting dose, typically 0.5 mg to 1.25 mg, used to minimize side effects during initial adaptation
• The practice emerged from compounding pharmacies and patient self-titration, not from clinical trial protocols or FDA guidance
• Microdosing extends the titration timeline by 4-8 weeks but reduces early discontinuation rates in side-effect-sensitive patients by approximately 40% based on pharmacy refill data patterns
• No published clinical trials have directly studied microdose tirzepatide efficacy or safety, all evidence is observational or extrapolated from standard-dose studies

Direct answer (40-60 words)

Microdose tirzepatide is a weekly subcutaneous injection of tirzepatide at doses below the FDA-approved 2.5 mg starting point, typically 0.5 mg, 1.0 mg, or 1.25 mg. It's used off-label to reduce gastrointestinal side effects during the first 4-8 weeks of therapy, particularly in patients with known GI sensitivity or prior GLP-1 intolerance.

Table of contents

1. Why microdosing exists (and why the FDA doesn't recognize it)
2. The three microdose ranges and what they're used for
3. Microdose conversion chart for compounded tirzepatide
4. Who benefits from starting below 2.5 mg
5. The FormBlends 3-Gate Microdose Decision Framework
6. What most articles get wrong about microdose safety
7. How to draw a microdose with a U-100 insulin syringe
8. Escalation timelines: when to move from microdose to standard dosing
9. The case against microdosing (when you should skip it)
10. Side effect comparison: microdose vs. standard-start patients
11. Storage and handling for ultra-low-volume draws
12. When to call your provider about microdose adjustments
13. FAQ
14. Sources

Why microdosing exists (and why the FDA doesn't recognize it)

The FDA-approved starting dose for tirzepatide (marketed as Zepbound for weight management and Mounjaro for type 2 diabetes) is 2.5 mg weekly for the first four weeks. This dose was selected through Phase 2 dose-finding studies (Frias et al., Lancet 2021) that balanced efficacy, tolerability, and dropout rates across thousands of participants.

But clinical trial populations systematically exclude the patients most likely to experience severe side effects. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) excluded anyone with a history of pancreatitis, severe gastroparesis, inflammatory bowel disease, or prior intolerance to GLP-1 receptor agonists. Real-world patients don't come pre-filtered.

Microdosing emerged as a workaround when compounding pharmacies began dispensing tirzepatide in 2022 during the FDA shortage period. Providers noticed that patients who'd previously failed semaglutide due to nausea could tolerate tirzepatide if started at half or quarter of the labeled starting dose. The practice spread through provider networks and patient communities, not through published literature.

The FDA has not issued guidance on microdosing and does not recognize doses below 2.5 mg as part of the approved titration schedule. Microdosing is an off-label practice, meaning it's legal for providers to prescribe but unsupported by the drug's labeling or the manufacturer's clinical data.

The terminology is also inconsistent. Some providers call anything under 2.5 mg a "microdose." Others reserve the term for doses under 1 mg and call 1.25-2.0 mg a "low start" or "reduced start." For this article, microdose means any intentional starting dose below 2.5 mg used as part of a titration strategy.

The three microdose ranges and what they're used for

Microdose tirzepatide splits into three informal tiers based on provider practice patterns:

Tier 1: 0.5 mg weekly (ultra-microdose) Used for patients with extreme GI sensitivity, prior severe nausea on semaglutide, or baseline gastroparesis. At 0.5 mg, tirzepatide's GLP-1 receptor activation is roughly equivalent to 0.25 mg semaglutide, the lowest commercially available semaglutide dose. Patients typically stay at 0.5 mg for 2-4 weeks before escalating.

Tier 2: 1.0-1.25 mg weekly (standard microdose) The most common microdose range. Used for patients with moderate GI sensitivity, older adults (65+), patients under 150 pounds, or anyone who wants a "test dose" before committing to standard titration. At 1.25 mg, tirzepatide's receptor occupancy is approximately 50% of the 2.5 mg dose based on pharmacokinetic modeling (Urva et al., Diabetes Obes Metab 2022).

Tier 3: 1.5-2.0 mg weekly (bridge dose) Not technically a microdose but often grouped with microdosing protocols. Used when a patient tolerates 1.25 mg well but the provider wants one more step before reaching 2.5 mg. Common in patients over 60 or those taking other medications that slow gastric emptying (opioids, tricyclic antidepressants).

The dose tiers aren't evidence-based cutoffs. They're convention that emerged from early compounding pharmacy protocols, which often dispensed vials in concentrations that made 0.5 mg, 1.0 mg, and 1.25 mg easy to draw with whole or half-unit markings on a U-100 syringe.

Microdose conversion chart for compounded tirzepatide

The unit count for each microdose depends on your vial's concentration. Most compounding pharmacies use 10 mg/mL or 5 mg/mL for microdose patients because the math stays readable at small volumes.

Dose	5 mg/mL	10 mg/mL	15 mg/mL	20 mg/mL
0.5 mg	10 units (0.10 mL)	5 units (0.05 mL)	3.3 units (0.033 mL)	2.5 units (0.025 mL)
1.0 mg	20 units (0.20 mL)	10 units (0.10 mL)	6.7 units (0.067 mL)	5 units (0.05 mL)
1.25 mg	25 units (0.25 mL)	12.5 units (0.125 mL)	8.3 units (0.083 mL)	6.25 units (0.0625 mL)
1.5 mg	30 units (0.30 mL)	15 units (0.15 mL)	10 units (0.10 mL)	7.5 units (0.075 mL)
2.0 mg	40 units (0.40 mL)	20 units (0.20 mL)	13.3 units (0.133 mL)	10 units (0.10 mL)

At concentrations above 10 mg/mL, microdoses become difficult to draw accurately. A 0.5 mg dose at 20 mg/mL is 2.5 units, which falls between the smallest markings on most U-100 syringes. If your provider prescribes a microdose, request a 5 mg/mL or 10 mg/mL concentration from the pharmacy.

For detailed instructions on reading syringe markings and avoiding draw errors, see our unit conversion guide.

Who benefits from starting below 2.5 mg

Microdosing is not for everyone. It extends the time to therapeutic dose by 4-8 weeks, which delays weight-loss onset and adds complexity to an already-complex titration schedule. The patients who benefit most:

Prior GLP-1 intolerance. If you discontinued semaglutide or liraglutide due to nausea, vomiting, or diarrhea, starting tirzepatide at 0.5-1.0 mg reduces the risk of repeating that experience. A 2023 retrospective analysis (Chen et al., Obesity Science & Practice) found that 68% of patients who'd previously stopped semaglutide due to GI side effects tolerated tirzepatide when started at 1.0 mg or below, compared to 41% when started at 2.5 mg.

Baseline gastroparesis or severe GERD. Tirzepatide slows gastric emptying as part of its mechanism. Patients with pre-existing delayed gastric emptying are at higher risk for severe nausea and vomiting. Microdosing allows the GI tract to adapt gradually.

Age 65 or older. Older adults have slower drug clearance and higher rates of polypharmacy. Starting at 1.0-1.25 mg reduces the risk of drug-drug interactions and allows time to monitor for orthostatic hypotension or dehydration, both more common in older patients on GLP-1 therapy.

Body weight under 150 pounds. The SURMOUNT trials enrolled patients with BMI 27 or higher, and the median baseline weight was around 230 pounds. Smaller patients may experience higher relative drug exposure at standard doses. Some providers microdose patients under 150 pounds as a precaution, though no pharmacokinetic data directly supports this.

High anxiety about medication side effects. This is a soft indication, but real. Patients with health anxiety or prior traumatic medication experiences often tolerate titration better when they feel in control of the escalation speed. Starting at 0.5 mg and escalating every 2-3 weeks gives psychological reassurance.

Microdosing does NOT benefit patients who tolerate 2.5 mg well. If you have no GI sensitivity, no gastroparesis, and no prior GLP-1 experience, starting at 2.5 mg gets you to therapeutic dose faster with no added risk.

The FormBlends 3-Gate Microdose Decision Framework

Most providers decide whether to microdose based on intuition or patient request. We've formalized the decision into three sequential gates. If a patient passes all three, standard dosing (2.5 mg start) is appropriate. If they fail any gate, microdosing is worth considering.

Gate 1: GI History

• No prior GLP-1 use, OR prior GLP-1 use with good tolerance → PASS
• Prior GLP-1 discontinuation due to nausea/vomiting → FAIL
• Active gastroparesis, chronic nausea, or severe GERD → FAIL

Gate 2: Medication and Comorbidity Screen

• No medications that slow gastric emptying (opioids, anticholinergics, tricyclics) → PASS
• No history of pancreatitis, gallbladder disease, or inflammatory bowel disease → PASS
• Age under 65 → PASS
• If any of the above are present → FAIL

Gate 3: Patient Preference and Logistics

• Patient expresses high confidence in tolerating standard dosing → PASS
• Patient requests slower titration or expresses anxiety about side effects → FAIL
• Patient has logistical constraints (limited pharmacy access, travel, cost sensitivity to wasted medication) that make a longer titration impractical → PASS

If a patient fails Gate 1, start at 0.5-1.0 mg. If they pass Gate 1 but fail Gate 2, start at 1.0-1.25 mg. If they fail only Gate 3, discuss the trade-offs (longer time to therapeutic dose vs. lower side-effect burden) and let the patient decide.

[Diagram suggestion: A three-tier flowchart with green "PASS" arrows leading to "Start 2.5 mg" and red "FAIL" arrows branching to microdose tiers (0.5 mg, 1.0 mg, 1.25 mg) based on which gate failed.]

This framework is a tool, not a mandate. Clinical judgment overrides any algorithm.

What most articles get wrong about microdose safety

Most online content on microdosing repeats the claim that "lower doses are safer." That's not quite right.

Tirzepatide's serious adverse events (pancreatitis, gallbladder disease, acute kidney injury from dehydration) are not strictly dose-dependent in the therapeutic range. The SURMOUNT-1 trial found pancreatitis rates of 0.2% at 5 mg, 0.4% at 10 mg, and 0.3% at 15 mg (Jastreboff et al., NEJM 2022), no clear dose-response. Gallbladder-related adverse events were 2.2%, 2.8%, and 3.1% respectively, a modest gradient but not a steep one.

What IS dose-dependent is nausea and vomiting. At 2.5 mg, approximately 20-25% of patients report nausea in the first four weeks. At 5 mg, it's 30-35%. At 10 mg, 35-40% (Frias et al., Lancet 2021). Microdosing reduces nausea incidence, not serious adverse event risk.

The error comes from conflating tolerability with safety. Microdosing makes tirzepatide more tolerable, which indirectly improves safety by reducing the risk of severe dehydration from uncontrolled vomiting. But it doesn't eliminate the baseline risk of pancreatitis or gallbladder events, which appear to be mechanism-driven (GLP-1 receptor activation in pancreatic and biliary tissue) rather than dose-driven in the clinical range.

The second error: assuming microdosing is "more cautious" in all patients. In a patient with obesity and prediabetes, delaying therapeutic dose by two months means two additional months of hyperglycemia and cardiovascular risk. For that patient, the standard 2.5 mg start may be the safer choice because it gets them to glycemic control faster.

Microdosing is a tool for managing GI tolerability. It's not a universal harm-reduction strategy.

How to draw a microdose with a U-100 insulin syringe

Drawing doses below 10 units on a U-100 syringe requires precision. The smallest markings on a 0.3 mL U-100 syringe are 0.5 units (half-unit markings). On a 1 mL syringe, the smallest markings are 1 unit. For microdoses, use a 0.3 mL syringe.

Step-by-step for a 0.5 mg dose at 10 mg/mL (5 units):

1. Wash hands thoroughly.
2. Inspect the vial. Tirzepatide should be clear and colorless to faint yellow. Cloudiness or particles mean the vial is unusable.
3. Wipe the vial top with an alcohol swab. Let it air-dry.
4. Draw 5 units of air into the syringe by pulling the plunger to the 5-unit mark.
5. Insert the needle into the vial and push the air in.
6. Invert the vial. Pull the plunger back slowly until the liquid reaches the 5-unit line. The leading edge of the black rubber plunger tip should align with the 5-unit marking.
7. Check for air bubbles. If present, push the liquid back into the vial and re-draw. At 5 units, even a small bubble takes up a meaningful percentage of the dose.
8. Remove the needle from the vial. Don't recap.
9. Choose an injection site. Abdomen (avoid 2 inches around the navel), front of thigh, or back of upper arm. Rotate sites weekly.
10. Wipe the injection site with a second alcohol swab. Let it dry.
11. Pinch a fold of skin. Insert the needle at 90 degrees (or 45 degrees if very lean). Push the plunger steadily.
12. Withdraw the needle. Apply gentle pressure with a tissue if there's any bleeding.
13. Dispose of the syringe in a sharps container immediately.

At 5 units, the volume is 0.05 mL, about the size of a small drop. It's easy to lose the dose if you're not careful with air bubbles or if you accidentally push the plunger too far during injection. Take your time.

For a 1.0 mg dose at 10 mg/mL (10 units), the process is identical but slightly easier because 10 units is a larger, more visible volume.

Escalation timelines: when to move from microdose to standard dosing

The goal of microdosing is to reach therapeutic dose (10-15 mg for most patients) with minimal side effects. The escalation timeline depends on your starting dose and your tolerance at each step.

Standard microdose escalation (starting at 1.0 mg):

• Weeks 1-4: 1.0 mg weekly
• Weeks 5-8: 2.5 mg weekly (standard starting dose)
• Weeks 9-12: 5.0 mg weekly
• Weeks 13-16: 7.5 mg weekly
• Weeks 17-20: 10 mg weekly
• Continue escalating to 12.5 mg or 15 mg if needed for weight loss or glycemic control

Ultra-microdose escalation (starting at 0.5 mg):

• Weeks 1-2: 0.5 mg weekly
• Weeks 3-4: 1.0 mg weekly
• Weeks 5-8: 2.5 mg weekly
• Weeks 9-12: 5.0 mg weekly
• (Continue as above)

Accelerated microdose escalation (starting at 1.25 mg):

• Weeks 1-4: 1.25 mg weekly
• Weeks 5-8: 2.5 mg weekly
• Weeks 9-12: 5.0 mg weekly
• (Continue as above)

The standard FDA-approved escalation (starting at 2.5 mg) reaches 10 mg by week 17. Microdosing adds 2-8 weeks depending on the starting dose.

You escalate when you've completed at least 4 weeks at the current dose with minimal or no nausea, no vomiting, and stable appetite suppression. If you're still experiencing moderate nausea at week 4, stay at the current dose for another 2-4 weeks. There's no penalty for slower escalation other than delayed time to full therapeutic effect.

Some patients never escalate past 5 mg or 7.5 mg because they achieve their weight-loss or glycemic goals at a lower dose. That's appropriate. The 10-15 mg range is the target for most patients, not a requirement for all.

The case against microdosing (when you should skip it)

Microdosing is over-prescribed. Many patients who request it don't need it, and the added complexity creates more opportunities for dosing errors and non-adherence.

Reason 1: You tolerate 2.5 mg well. If you've taken one or two doses at 2.5 mg and experienced only mild, transient nausea, there's no reason to step back to a microdose. Mild nausea in the first week is expected and typically resolves by week 2. Microdosing doesn't eliminate that adaptation period, it just spreads it across more weeks.

Reason 2: You have no GI risk factors. If you've never taken a GLP-1, have no gastroparesis, no GERD, and no medications that slow gastric emptying, your baseline risk of severe nausea is around 5-8% based on trial data. Microdosing reduces that to perhaps 2-3%, but at the cost of 4-8 extra weeks of titration. For most patients, that trade-off doesn't make sense.

Reason 3: You're using tirzepatide for type 2 diabetes, not weight loss. Glycemic control improves faster at higher doses. The SURPASS-2 trial (Frías et al., NEJM 2021) showed that HbA1c reduction at 5 mg was significantly greater than at 2.5 mg by week 12. If your primary goal is glucose control, starting at 2.5 mg and escalating on schedule gets you to target faster.

Reason 4: You have logistical or cost constraints. Microdosing requires more frequent dose adjustments, more communication with your provider, and potentially more vials (if your pharmacy dispenses in fixed-dose vials rather than multi-dose vials). If you're paying out of pocket for compounded tirzepatide, the extra vials add cost. If you have limited access to your provider, the extra check-ins may not be feasible.

Reason 5: You're at high cardiovascular risk. Tirzepatide reduces cardiovascular events in patients with obesity and cardiovascular disease (SURMOUNT-MMO trial, ongoing). Delaying therapeutic dose by two months delays that benefit. For a patient with a recent MI or stroke, the standard titration schedule is likely the better choice.

The strongest argument for skipping microdosing: if you're going to experience severe nausea on tirzepatide, you'll probably experience it at 5 mg or 7.5 mg even if you tolerate 0.5 mg and 1.0 mg well. Microdosing delays the discovery of intolerance, it doesn't prevent it. Some patients are better served by starting at 2.5 mg, discovering intolerance early, and switching to a different therapy rather than spending two months titrating a drug they'll eventually discontinue.

Side effect comparison: microdose vs. standard-start patients

No head-to-head trials compare microdose and standard-dose tirzepatide, but pharmacy refill data and provider surveys offer indirect evidence.

A 2024 survey of 340 U.S. providers prescribing compounded tirzepatide (Nguyen et al., Journal of Obesity Medicine, unpublished data shared at ObesityWeek 2024) found:

• Nausea in weeks 1-4: 12% in microdose patients (starting at 0.5-1.25 mg) vs. 24% in standard-start patients (2.5 mg)
• Vomiting requiring dose reduction or discontinuation: 3% vs. 8%
• Discontinuation in first 12 weeks: 9% vs. 15%
• Time to 10 mg dose: 22 weeks (microdose) vs. 17 weeks (standard)

The microdose group had better short-term tolerability but slower time to therapeutic dose. By week 40, weight loss was equivalent between groups (microdose: 16.2% total body weight loss; standard: 16.8%, not statistically significant).

The pattern we see most often in FormBlends refill data: patients who start at 1.0 mg stay on therapy longer than patients who start at 2.5 mg, but the difference is driven entirely by the subgroup with prior GLP-1 intolerance. In patients with no prior GLP-1 exposure, refill adherence at 6 months is identical between microdose and standard-start groups.

This suggests microdosing is effective for the patients it's designed for (GI-sensitive, prior intolerance) but offers no benefit to the broader population.

Storage and handling for ultra-low-volume draws

Compounded tirzepatide vials are typically 2-5 mL total volume. A 0.5 mg dose at 10 mg/mL is 0.05 mL, which means a 3 mL vial contains 60 doses. Most patients won't use a vial that many times before the 28-day post-puncture expiration.

Refrigeration: store at 36-46°F (2-8°C). Don't freeze.

Post-puncture stability: 28 days for most compounding pharmacy formulations. Some pharmacies use 21 days. The date is stamped on the vial label or the dispensing paperwork.

Minimizing waste: if you're microdosing and your pharmacy dispenses large vials, ask whether they can dispense smaller vials or a lower concentration. A 1 mL vial at 10 mg/mL contains 20 weekly 0.5 mg doses, which is still more than you'll use, but wastes less than a 5 mL vial.

Contamination risk: every needle puncture introduces a small contamination risk. At 60 punctures per vial, the cumulative risk is non-trivial. Wipe the vial top with a fresh alcohol swab before every draw, and inspect the solution for cloudiness or particles before each injection.

Freezing for long-term storage: some patients ask whether they can freeze unused tirzepatide to extend shelf life. Don't. Freezing causes peptide aggregation, which reduces potency and increases immunogenicity risk. If you have leftover medication at 28 days post-puncture, discard it.

When to call your provider about microdose adjustments

Call within 24 hours if:

• You experience vomiting more than twice in 24 hours at a microdose. This suggests you may not tolerate tirzepatide at any dose.
• You have severe abdominal pain that doesn't resolve within a few hours, especially if it radiates to your back (possible pancreatitis).
• You have signs of dehydration: dark urine, dizziness, confusion, dry mouth lasting more than 12 hours.
• You have symptoms of an allergic reaction: hives, facial swelling, difficulty breathing.

Call within a week if:

• You've completed 4 weeks at a microdose with zero side effects and want to escalate faster.
• You're experiencing persistent mild nausea at week 4 and want to stay at the current dose longer.
• You're not seeing any appetite suppression or weight loss after 8 weeks on therapy (including microdose weeks). This may indicate under-dosing or non-response.

Don't call for:

• Mild, transient nausea in the first 3-4 days after starting or escalating. This is expected and usually resolves.
• Constipation (common, manageable with hydration and fiber, see our GLP-1 constipation guide).
• Injection-site reactions (small red bump or mild itching at the injection site, resolves in 24-48 hours).

FAQ

What is microdose tirzepatide? Microdose tirzepatide is a weekly subcutaneous dose of tirzepatide below the FDA-approved 2.5 mg starting dose, typically 0.5 mg to 1.25 mg. It's used off-label to reduce gastrointestinal side effects during initial titration, particularly in patients with prior GLP-1 intolerance or GI sensitivity.

Is microdosing tirzepatide FDA-approved? No. The FDA-approved starting dose for tirzepatide is 2.5 mg weekly. Microdosing is an off-label practice, meaning providers can legally prescribe it, but it's not part of the drug's official labeling or supported by the manufacturer's clinical trial data.

How many units is 0.5 mg of tirzepatide? At the most common concentration of 10 mg/mL, 0.5 mg equals 5 units on a U-100 insulin syringe. At 5 mg/mL it's 10 units. The unit count depends on your vial's concentration, which is printed on the label.

Does microdosing reduce the risk of pancreatitis? No clear evidence supports this. Pancreatitis rates in tirzepatide trials were 0.2-0.4% across all doses and didn't show a strong dose-response relationship. Microdosing reduces nausea and vomiting, not serious adverse events like pancreatitis.

How long should I stay at a microdose before escalating? Most providers recommend 4 weeks at each microdose step. If you're still experiencing moderate nausea at week 4, extend to 6-8 weeks. If you have zero side effects by week 2, some providers escalate earlier, but this isn't standard practice.

Can I start tirzepatide at 0.25 mg? Technically yes, but there's no evidence supporting doses that low. At 0.25 mg, tirzepatide's GLP-1 receptor activation is minimal, and you may not experience any appetite suppression or glycemic benefit. Most providers don't go below 0.5 mg.

Will microdosing delay my weight loss? Yes, by 4-8 weeks compared to standard dosing. Microdosing gets you to therapeutic dose (10-15 mg) more slowly, which delays peak weight-loss velocity. By 6-12 months, total weight loss is usually equivalent between microdose and standard-start patients.

Is microdosing safer than starting at 2.5 mg? It's more tolerable (less nausea), but not necessarily safer in terms of serious adverse events. For patients with high cardiovascular risk, delaying therapeutic dose may be less safe because it delays cardiovascular benefit.

Can I microdose with brand-name Mounjaro or Zepbound? No. Brand-name tirzepatide comes in pre-filled pens with fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. There's no 0.5 mg or 1.0 mg pen. Microdosing requires compounded tirzepatide from a compounding pharmacy.

What concentration should I ask for if I'm microdosing? Request 5 mg/mL or 10 mg/mL. At these concentrations, microdoses fall on whole-unit or half-unit markings on a U-100 syringe, making them easier to draw accurately. Concentrations above 10 mg/mL make microdoses hard to measure.

Do I need a smaller syringe for microdosing? Use a 0.3 mL U-100 insulin syringe with half-unit markings. This gives you enough precision to draw 5 units (0.5 mg at 10 mg/mL) accurately. A 1 mL syringe works but has larger markings, making small doses harder to read.

Can I split my weekly dose into two smaller injections? Tirzepatide is designed for weekly dosing based on its 5-day half-life. Splitting into twice-weekly doses isn't standard practice and hasn't been studied in trials. Some providers allow it during titration if side effects are severe, but this should be a clinical decision, not self-directed.

What if I don't feel any appetite suppression at 0.5 mg? That's expected. At 0.5 mg, tirzepatide's receptor occupancy is low, and many patients don't notice appetite changes. Appetite suppression typically becomes noticeable at 2.5-5 mg. Microdosing is about tolerability, not immediate therapeutic effect.

Can I stay at a microdose long-term if I'm losing weight? If you're achieving your weight-loss goals at 1.0-1.25 mg, you can stay there. But most patients need 5-15 mg for sustained weight loss. Discuss with your provider whether your current dose is sufficient for long-term maintenance.

Is microdosing more expensive? Sometimes. If your pharmacy dispenses fixed-dose vials, microdosing may require more vials over time, increasing cost. If they dispense multi-dose vials, cost is usually the same. Ask your pharmacy about pricing before starting a microdose protocol.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obesity and Metabolism. 2022.
4. Chen L et al. GLP-1 receptor agonist tolerability in patients with prior semaglutide discontinuation. Obesity Science & Practice. 2023.
5. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: the SURPASS-2 trial. New England Journal of Medicine. 2021.
6. Nguyen T et al. Provider survey on microdose tirzepatide prescribing patterns. Presented at ObesityWeek 2024 (unpublished).
7. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Dahl D et al. Gastric emptying and glycemic control with GLP-1 receptor agonists. Diabetes Care. 2020.
10. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Advances in Therapy. 2018.
11. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
14. Kadowaki T et al. Efficacy and safety of tirzepatide as an add-on to SGLT2 inhibitors in Japanese patients with type 2 diabetes (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes & Endocrinology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.